Introduction
Many cancer therapeutic agents have been used for experimental and clinical purposes.
It has been established that generally such agents are toxic to embryos with highly mitotic activities as well as other rapidly growing or proliferating tissues. The teratogenicity of these agents has been shown in rodents (Reviewed by Nishimura, '64; Karnof sky, '65; Dagg, '66). Murphy et at. ('58) found that the effects of various alkylating .agents upon rat embryos were similar to each other, while some principal differences in teratogenic action existed between alkylating agents and antimetabolites.
Mitomycin is an antibiotic isolated in Japan from a new actinomyces strain named streptomyces caespitosus discovered by Hata et al. ('56) and has strong activity against various microbes and malignant tumor cells. Among three kinds of mitomycin, mitomycin C introduced by W a k a k i et at. ('58) was found to be the most stable and the least toxic one and has been applied in clinical use. The mechanism of action of mitomycin C has been established to be the inhibition of biosynthesis of nucleic acids, especially of DNA.
In a previous report, the author presented a comprehensive study on the effect of thio-TEPA, one of the potent antineoplastic alkylating agents, upon mouse embryos (T a n i m u r a, '68). The study to be reported here was designed to compare the effect of mitomycin C upon mouse embryos with the results obtained by the use of thio-TEPA.
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Materials and methods
The animals used in this experiment were Japanese colony bred dd stock mice, from the Animal Center Laboratory, Faculty of Medicine, Kyoto Uuiversity.
They were fed a compressed pellet (NMF) manufactured by the Orient Yeast Mfg. Ltd., Tokyo. Water was available ad libitum.
Virgin females of 10 to 1.3 weeks of age were mated all night with males. When a vaginal plug was found, the copulation day was designated as zero day of gestation. The pregnant mice were injected with mitomycin C intraperitoneally once on various days between 7$ and 13.5 of gestation at the dosage of 5.0, 7.5 or 10.0 mg/kg. Mitomycin C was dissolved in aqueous solution and the concentration was designed for a single dose to be 10 ml/kg of body weight.
All the mice were sacrificed on day 18.5 of gestation. The uterine horns were dissected and the implantation sites were surveyed. The live fetuses as well as their placentas were weighed and then examined_ for external gross malformations or changes. The fetuses of the group treated at the dosage of 7.5 mg/kg were cleared and stained with alizarin red S by a modified method of Dawson ('27) and were examined for skeletal abnormalities.
Some of the placentas were histologically examined.
Results
The dams treated with mitomycin C at the dosage of 5.0 mg/kg did not exhibit any ill-effects throughout their pregnancy. Four dams who received mitomycin C at 7.5 mg/kg died several days after the injection. Some of the survivors showed roughness of hair, emaciation or diarrhea. Six out of 26 dams who received mitomycin C at 10.0 mg/kg died and the survivors showed moderate symptoms as observed in the group treated at 7.5 mg/kg. At autopsy, a milky ascites was found in several of these cases.
The main findings in the offspring are summarized in tables 1 and 2-A and B.
A remarkably significant increase of fetal mortality was demonstrated in the treated groups except the group treated on day 13.5.. This lethal effect was especially conspicuous on day 8.5 and 9.5. As the developmental stage at which the drug was administered increased, the mortality declined. In general, as the dosage was increased, fetal mortality became higher. •r4 Sex ratio of the surviving fetuses was not altered. The average body weight of the surviving fetuses was significantly decreased in all the treated groups. The highest growth supressing effect was shown by treatment on day 11.5. An increased dosage generally resulted in a greater reduction of body weight. The average weight of placentas was also decreased in the treated groups in a manner almost parallel to the reduction of fetal weight. However, no notable macroscopic or histological changes were observed in the placentas.
Various malformations were induced in the offspring by treatment at 7.5 mg/kg between 7.5 and 12.5 days of gestation. W hen the agent was administered on day 13.5, a few anomalous fetuses were observed but the incidence was statistically insignificant compared with the control. All of the surviving fetuses of dams treated on days 8.5, 9.5 or 10.5 had external gross malformations. Treatment at stages later than 11.5 days did not produce 100% affected litters. The incidence of the malformed fetuses from dams receiving a dosage of 5.0 mg/kg was generally lower than that from the group treated at 7.5 mg/kg. Skeletal defects in the extremities, palate or tail were the most common malformations and other anomalies such as eye defects and malformations of the abdominal wall were also found in low incidences.
Type of anomalies and their incidences were mainly determined by the time when the agent was applied.
Two cases of hydrocephalus and one case of encephalocele were noted by the treatment on day 10.5 at the dosage of 7.5 mg/kg. Ex encephaly was observed only in the group treated on day 7.5. Open eyelids were demonstrated in relatively a few cases. The critical period for this anomaly is estimated to be day 12.5 and 13.5. Cleft palate was fairly frequently produced by the treatment on day 8.5 to 13.5 but day 12.5 seems to be most sensitive with respect to this anomaly. Complete and wide fissure of the palate was shown in most cases ( fig. 10 ). Micrognathia was mostly associated with cleft palate. It seems that the critical period for this anomaly is day 10.5 to 13.5, with day 10.5 being the most sensitive.
General hydrops especially marked in the trunk was observed in 3 cases. Two of these were from dams treated on day 13.5 at 7.5 mg/kg and the other case from a dam treated on day 10.5 at 5.0 mg/kg. Umbilical hernia was noted only in one case treated on day 12.5 at the dosage of 10.0 mg/kg. Two types of tail abnormalities were found, the first was shortening in length, often with sharply tapered tips and the second kinking, curling or bending with the shape of Ti or S. These two types were often combined with each other. The critical period for the former seems to be broader (day 8.5 to 11.5) than that for the latter (day 8.5 to 9.5).
Miscellaneous abnormalities of the limbs were noted. Micromelia, which was more often in the forelimbs, was produced by the treatment on day 10.5 or 11.5, especially on the former day. Some of them appeared as hypoplastic forepaws directly attached to trunks ( fig. 3 ). In the cleared specimens, fusion of humerus with radius together with or without ulna was observed in many cases (figs. 11 and 12). Sometimes both radius and ulna were not demonstrated ( fig. 13 ). In an extreme case, only a small spot was recognized as a free appendage while the scapula showed an elongated club-like particle. The clavicle was often slender, short or dotted. The radius was sometimes independently affected, exhibiting a short or curved shape. Usually the ulna was affected less severely than radius. Abnormalities of the hind limbs were also noted in many cases. Some cases of club foot and pes valgus were observed by the treatment on day 7.5 to 9.5, but the complicated distorsion of the leg combined with the anomalies of ankle joint were often noted in fetuses treated on day 10.5 ( fig. 4 ). In the cleared specimens, many abnormalities in the skeleton of hind limb were demonstrated. In the pelvic girdle, such anomalies as fusion between the ischium and pubis (sometimes even the ilium was involved ( fig. 14) ), parted pubis, severely hypoplastic pubis, or flexure of ilium were noted by the treatment on day 10.5 or 11.5. Treatment on day 13.5 resulted in a characteristic anomaly with abnormally ossified spots adjacent to the ossification center of the pubis, which almost always were associated with the similar calcification in both sides of the ossified vertebral bodies. The femur was sometimes small or bent, often in association with the anomalies of the pelvis. The tibia was often small or curved and occasionally was associated with defect of the fibula. Absence of both tibia and fibula was noted in a few cases. Osseous fusion of femur with tibia and fibula was observed only in one case ( fig. 15 ), while cases with the corresponding fusion in the forelimb were often found as described above.
Anomalies of the digits might be classified into (a) overgrowth, that is poly-or macrodactyly and (b) reduction, that is oligo-or brachydactyly.
In the forelimb, the anomalies were limited almost to reduction.
Polysyndactyly was rarely observed. Various intermediate forms of reductive processes, oligodactyly and syndactyly in combination with brachydactyly or maldirection of digits were noted and the precise classification was difficult. The main types of these anomalies are listed in figure 1. The lack of the second digit was most common. In severely affected cases with micromelia, only rudimentary small knots were attached to trunk, hardly recognized as digits. In the hind limbs the reductive process was sometimes cornbined with overgrowth, which resulted in the complicated malformations. Overgrowth alone was observed in many cases (fig. 6 ). The critical period for this anomaly seems to fall between day 8.5 and 11.5, which is comparatively earlier than that for reduction. Macrodactyly was exclusively limited to the hallux.
Also polydactyly existed most commonly in that digit and occasionally the second, third or fourth digit.
A fetus in the group treated on day 10,5 showed hematoma in both hind paws ( fig. 5 ). The types of overgrowth are shown in figure 2. In the cleared specimens, retardation of ossification was severe in every treated group, especially in the ones treated on days 10.5 to 13.5.
Abnormalities of the axial skeleton were observed frequently in the cleared specimens.
The vertebrae were affected by treatment between day 7.5 and 11.5 with the peak effect on day 10.5. Occasionally cervical vertebrae were fused with one another at the posterior end of the arches showing a comb-like shape ( fig. 7) . Sometimes the exoccipital bone was also affected. The upper part of the thoracic vertebral column was sometimes fused. This was noted chiefly in fetuses treated on day 10.5. Sometimes, fusion of the body with both arches of the vertebra at the corresponding level was noted in fetuses treated on day 10.5 ( fig. 8 ). Treatment on day 7.5 or 8.5, resulted in fusion between two or three adjacent vertebral arches in the cervical or thoracic region. In fetuses treated on day 8.5, the ossification centers of the bodies of all the vertebrae lower than the thoracic level were divided into two parts, while the bodies in the cervical region were not ossified. Malformations were rarely found in fetuses treated on day 11.5 to 13.5, but retardation of ossification especially in the posterior arches of the cervical vertebrae was manifest. Frequency of the fetuses with cervical ribs was significantly lower in the groups treated later than day 10.5 compared with the control, but the general retardation of ossification might mask the existence of cervical rib. Rib abnormalities were also observed in many cases. Variation in the number of ribs was to some extent associated with the stage when the agent was applied.
Most of the fetuses which received treatment on day 7.5 or 8.5 had 14 ribs. In the group treated on day 11.5, cases with only 12 or even 11 ribs were found. Fusion of the ribs were noted in the group treated on day 7.5 or 8.5. Anomalies of individual ribs such as waviness, sharp bending, shortening were observed in the cases treated on day 10.5 to 13;5 and in most instances these were combined with severe retardation of ossification of the ribs ( fig. 8 ). Sometimes, partly ossified ribs with small Or non-ossified proximal part were found in the group treated on day 10.5 or 11.5. Occasionally. extraordinary ossification of the sternal part of rib cartilage accompanied by severely retarded ossification of the whole skeleton was noted in the group treated on day 13.5. In the cases treated on day 10.5 to 13.5 (especially on day 13.5), the grade of ossification of various ribs was not uniform ; the ribs at the middle thoracic level remained unossified while those in the upper and lower levels were well ossified. Number of ossified coccygeal vertebrae was significantly decreased in every treated group except the one treated on day 9.5.
Retardation of ossification of the sternebrae was prominent in all the treated groups.
Sternebra No. 5 was often missing, parted or small. Fusion between the sternebrae in the lower position was often noted in the group treated on day 10.5. Most of them were broad fusion giving a board-like appearance.
Sometimes, an abnormally long sternebra No. 6 was observed ( fig. 9 ) and also irregularity of rib cartilage adjacent to the sternebra.
Discussion
The results show that mitomycin C administered to pregnant mice has teratogenic, lethal and growth suppressing effects. The frequency and types of anomalies are dependent upon the dosage and the time when the agent is applied.
Embryotoxic effects of mitomycin C have been studied by a few investigators.
Ma t s u m o t o ('58) studied the effects of combined administration of radiation and mitomycin C to chick embryos. Also S a s a n u m a ('60) injected this agent into the yolk sac of chick embryos on the 4th, 8th or 12th day of incubation and growth inhibition and developmental abnormalities including micromelia and evisceration of the abdominal viscera resulted. The effect was most severe with treatment on day 4, but never observed on day 12. K u r y and C r a i g ('67) injected mitomycin C into the yolk sac of chick embryos on the 3rd or the 4th day of incubation at 2 to 28 pg/egg and observed retardation of growth and malformations such as microphthalmia and abnormalities of beak and lower extremities. M u r ph y ('62) administered mitomycin C to rats on the 11th or 12th day of gestation and found that the fetal minimun LD100 was 2.0 to 2.5 mg/kg, and that 1.5 mg/kg was non-lethal and non-teratogenic to fetuses. Even higher doses were found to be non-teratogenic. T a k ay a ('65) injected mitomycin C at 0.4 to 0.8 mg/kg to pregnant rats on day 6 to 10 or 10 to 14 of gestation and found a decrease of fetal body weight, a marked increase in fetal mortality and in the incidence of malformed fetuses. The main types of anomaly were anand microphthalmia and hydronephrosis. Nish i m u r a and Dag g (unpulished) briefly reported strain differences in response to the teratogenic effect of mitomycin C administered intraperitoneally to pregnant mice on day 10 at 1 to 3 mg/kg. Endo et al. ('65) administered mitomycin C by one single injection intraperitoneally to pregnant mice of CF, stock at 2 to 10 mg/kg during the period from the 10th to 13th days of gestation.
A high incidence of defects in the offspring was shown by this treatment at a dosage of more than 7.5 mg/kg and no significant increase of anomalies was observed when treated at less than 5 mg/kg. The main types of anomaly were cleft palate, short tail, wavy ribs, micrognathia and oligodactyly. Fetal mortality, on the other hand, was manifest even by the treatment at 5 mg/kg. They concluded that the lethal and growth-retarding effects of mitomycin C upon mouse embryos were not always paralleled with the teratogenic effect. Their results are very similar to some of those in the present study.
The critical period for some anomalies is presented in table 3, in comparison with the results obtained by the author ('68) using the same dose of thio-TEPA.
Generally, there exists a similarity between the two drugs although some differences exist in the details. The effects of mitomycin C are generally more intensive than those of the same dose of thio-TEPA. This is shown especially in the extremities.
Some notable differences exist with respect to vertebral anomalies.
With thio-TEPA, a clear cut picture of cephalocaudal progression with successive treatment days was shown. This was also demonstrated by Ingalls and Curley ('57), in experiments using hypoxia as a teratogenic agent. Treatment with thio-TEPA on clay 10.5 resulted in only a few cases of anomaly in the caudal region. In case of mitomycin C, the broad fusion of adjacent cervical arches was observed in the group treated on day 10.5. Moreover, the bilaterally split ossification centers in the bodies throughout the whole vertebral column were produced by the treatment on day 8.5. This type of abnormal ossification was also induced by X-irradiation (R u s s e 1 I, '56) and by the application of 6-aminonicotinamide (P i n s k y and F rase r, '59). It was not produced by thio-TEPA. G r U neberg ('63) described similar bilateral or twin ossification centers in the mutant mice with undulated, screw tail and other malformation.
The structual formula of mitomycin C was established in 1962
(W e b b et al. '62). It is characterized as a combinative constitution of three representative antineoplastic chemical groups ; urethan, quinone and ethylenimine.
This structure would account for the potent teratogenic activity of mitomycin C which is to some extent similar to thio-TEPA (T animura '68), which is one of the ethylenimine compound, and to urethan (N ishimura and Kuginuk i, '58). The explanation of some of the differences shown on the effects between thio-TEPA and mitomycin C, must await further metabolic studies with both compounds. Actinomycin D, an antibiotic isolated by W a k s m a n and W o o dr u f f ('40) has not only antimicrobial properties but also a marked cytotoxic action (P u g h et al. '56) . T u c h m a n n-D u p 1 e s s i s and Me r c i e r-P a r o t ('58, '60) showed a remarkable teratogenic activity of this antibiotic in rats and rabbits. They stressed that the teratogenicity was proven in rats at a dose of 50 pg/kg which is four to five times less than the therapeutic dose. This dosage was far lower than the teratogenic dose of mitomycin C used in this study. In the case of mitomycin C, the dose used in this experiment (5.0 to 10.0 mg/kg) was over 100 times higher than the human therapeutic dose (0.04 mg/kg). Mitomycin C is known to inhibit selectively the synthesis of DNA (S h i b a et al. '59), while Reich et at. ('62) proposed that actinomycin. D blocks RNA synthesis. On the basis of the study of the effects of both agents on in viva synthesis of nucleic acids, it was found that both inhibit the incorporation of labelled thymidine with DNA, but mitomycin C acts promptly while the effect of actinomycin D is characterized by a relatively long period of latency (S c h w a r t z et al. '63). It might be concluded that both antibiotics are useful tool for further comparative analytical studies for elucidating the mechanism of teratogenicity of chemical agents.
Summary
Pregnant mice of Japanese colony bred dd stock were injected intraperitoneally with mitomycin C, a potent antineoplastic antibiotic, once on various days between 7.5 and 13.5 of gestation at the dosage of 5.0, 7.5 or 10.0 mg/kg. They were sacrified at term and their fetuses were examined for external development. The fetuses treated at the dosage of 7.5 mg/kg were cleared and stained with alizarin red S for the study of skeletal development. The findings may be summarized as follows.
1. Significantly increased fetal mortality was noted in all the groups treated on day 7.5 to 12.5. It was highest in the group treated on day 9.5 at the dosage of 7.5 mg/kg. No change in sex ratio was found in the surviving fetuses.
2. Growth supression in the surviving fetuses was recognized by treatment at all stages, and was especially remarkable in the groups treated between 10.5 and 12.5.
3. Gross external anomalies were observed in all the treated groups, except in the group treated at 7.5 mg/kg on day 13.5. The types of anomalies were as follows : Brain anomalies such as exen-cephaly, open eyelids, cleft palate, micrognathia, umbilical hernia, short or kinky tail, micromelia, anomalies of the ankle joint and multiple digital malformations such as reduction and overgrowth. Among these, anomalies in the skeletal system were most common. The type of anomaly seems to be determined principally by the developmental stage when mitomycin C was applied.
4. Reduction of dose produced less lethality. Teratogenicity with the dose 7.5 mg/kg was higher than with 5.0 mg/kg.
5. In addition to those external anomalies, other skeletal abnormalities were demonstrated in the cleared specimens of the treated group. General retardation of ossification was frequently recognized. In the groups treated on day 10.5 to 13.5, its incidence was particularly high corresponding to the tendency of reduction of the average body weight. In the extremities, slender scapula, fusin of long bones in micromelic forelimbs, fusion between pubis and ischium, curved. tibia, occasionally accompanied with hypoplastic femur, etc. were demonstrated. Vertebral anomalies were also observed. These included fusion of several cervical arches in the group treated on day 10.5, and bilateral ossification centers in many adjacent vertebral bodies in the group treated on day 8.5. Rib abnormalities including fusion, waviness, bending, abnormal ossification and alteration in number were observed. Fusion of sternebrae was also noted.
6. In general, the types of anomalies induced with mitomycin C are the same as those produced by thio-TEPA administered by a similar procedure.
7. The weight of placenta was decreased in the treated groups and its grade was almost parallel to the reduction of fetal body weight. No pathological findings in placentas, however, were noted macroscopically and histologically. on day 10. 
